Abstract:Abstract Despite the success achieved by antiretroviral HIV-1 therapies, long-term and repeated drug administration is associated with toxicity, virus evasion and high cost. We aim to develop a gene therapy approach for persistent control against HIV-1 infection by delivering the transgene expressing a decoy receptor (eCD4-Ig) to hematopoietic stem cells (HSCs) by in vivo transduction. In this approach, HSCs are mobilized from the bone marrow into the peripheral blood stream and transduced with intravenously injected virus vectors. We use an integrating, helper-dependent adenovirus (HDAd5/35++) vector system that targets human CD46, a receptor that is abundantly expressed on primitive HSCs. Transgene integration is achieved by a hyperactive Sleeping Beauty transposase and transgene marking in peripheral blood cells can be increased by in vivo selection. The efficacy and safety of our in vivo HSC transduction/selection strategy has been previously demonstrated for the treatment of b-hemoglobinopathies, hemophilia A, and cancer in murine disease models. In non-human primates, we showed efficient transgene (g-globin) expression in peripheral red blood cells using this strategy. eCD4-Ig functions like a neutralizing antibody and shows broad neutralization spectrum against HIV-1, HIV-2 and SIV isolates. We have designed and produced an HDAd5/35++ vector expressing rhesus eCD4-Ig (rh-eCD4-Ig) from a constitutive and highly active EF1a promoter. In CD46-transgenic mice, over 50μg/mL eCD4-Ig in serum was measured after in vivo transduction and selection, with no obvious adverse events observed. Neutralization assay with serum samples showed that the produced eCD4-Ig effectively inhibited HIV-1 and SIV infection. We then performed studies in a rhesus macaque. After in vivo HSC transduction/selection of a rhesus macaque, eCD4-Ig serum levels were stable at 20-30 mg/ml. In vitro SIVmac239 neutralization assays using week 13 serum and recombinant eCD4-Ig protein determined that the IC50 of eCD4-Ig in rhesus serum is 1.0 mg/ml. This implies that the serum eCD4-Ig concentration at the time of SIVmac239 challenge was ~25-fold higher than the IC50. High-level eCD4-Ig expression had no clinical or hematological side effects. The first SIVmac239 challenge (20pg) was given on June 22 nd. Increasing rechallenge doses are currently injected monthly. So far, the viral load measured by quantitative RT-PCR is below detection limit. The animal is without symptoms and has normal lymphocyte/subset counts. Our study demonstrates an in vivo HSC transduction approach for potential long-term control of HIV-1 infection. Disclosures Kiem: VOR Biopharma: Consultancy; Ensoma Inc.: Consultancy, Current holder of individual stocks in a privately-held company; Homology Medicines: Consultancy. Lieber: Ensoma: Research Funding.

Development of real-time PCR for quantitation of simian immunodeficiency virus 2-LTR circles

Establishment of a Real-Time Fluorescent Quantitative PCR for the Rapid Detection of Viral Reservoir in the Peripheral Blood of SIV-infected Rhesus Monkeys

Quantifying integrated SIV-DNA by repetitive-sampling Alu-gag PCR

Quantitation of Simian Immunodeficiency Virus (SIV) and SHIV Virus RNA Load Using Real-Time Quantitative RT-PCR with TaqMan Probe

Establishment of a Real-Time RT-PCR to Detect Plasma Viral Load of Simian/human Immunodeficiency Virus CN97001 During Its in Vivo Passage in Rhesus Monkeys

Comprehensive Mapping of SIVmac239 Envelope Antigenic Determinants Recognized by Specific Polyclonal Antibodies in Vaccinated And/or Infected Macaques (P4503)

Dynamic Decay of Viral Reservoirs in Systemic and Lymphoid Compartments of SIV-infected Rhesus Macaques on Long-Term Combined Antiretroviral Therapy

Development of Droplet Digital PCR-Based Assays to Quantify HIV Proviral and Integrated DNA in Brain Tissues from Viremic Individuals with Encephalitis and Virally Suppressed Aviremic Individuals

Comprehensive Mapping of SIVmac239 Envelope Antigenic Determinants Recognized by Specific Polyclonal Antibodies in Vaccinated And/or Infected Macaques

A real time PCR platform for the simultaneous quantification of total and extrachromosomal HIV DNA forms in blood of HIV-1 infected patients

Validation of a pan-orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman primate blood

Determination Of Virus Burst Size In Vivo Using A Single-Cycle Siv In Rhesus Macaques

Application of Nested-PCR in Detection of Chimeric Simian/human Immunodeficiency Virus in Animal Infection Model

Early Sites of Virus Replication After Oral SIVmac251 Infection of Infant Macaques: Implications for Pathogenesis

Variable Baseline Papio cynocephalus Endogenous Retrovirus (PcEV) Expression Is Upregulated in Acutely SIV-Infected Macaques and Correlated to STAT1 Expression in the Spleen

Immunologic And Virologic Mechanisms For Partial Protection From Intravenous Challenge By An Integration-Defective Siv Vaccine

A 16-color full spectrum flow cytometric analysis for comprehensive evaluation of T-cell reconstitution in SIV-infected rhesus macaques

Persistent Control of SIV Infection in Rhesus Macaques By Expressing a Highly Potent SIV Decoy Receptor after In Vivo HSC Transduction

Single cell spatial profiling of FFPE splenic tissue from a humanized mouse model of HIV infection

Early pathogenesis of disease caused by SIVsmmPBj14 molecular clone 1.9 in macaques

Development and Validation of Quantitative PCR Method for Studying Biodistribution of a HIV-PV DNA Vaccine in Mice